(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
L.A.'s most famous midcentury home, the Stahl House, is on the market for the 1st time, at $11K per square foot: See inside- Germany's Bundestag extends two armed forces missions abroad
- Famous Places to get-away for Americans
- JFK's granddaughter reveals terminal cancer diagnosis, criticizes cousin RFK Jr.
- Eat Well, Live Well: An Extensive Manual for Smart dieting and Sustenance
- Grasping Wrongdoings and Crimes: A Correlation
- A quick recap of 'Stranger Things' Seasons 1-4, plus key episodes to rewatch before Volume 1 of the final season drops
- True serenity: Investigating Emotional well-being and the Advantages of Contemplation
- Astounding Treehouses All over the Planet
